Get it on Google Play

Upstream Bio presents additional Phase 2 data for nasal polyp treatment

March 1, 2026 9:45 AM UTC Send to a Friend
Upstream Bio Inc. (NASDAQ: UPB) presented additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login